Editas Medicine Inc (EDIT) gained Tuesday morning as the stock rose 2.06% in pre-market trading to 59.4. EDIT’s short-term technical score of 57 indicates that the stock has traded more bullish in the past month than 57% of stocks in the market. In the biotechnology industry, which ranks 139 out of 146 industries, Editas Medicine Inc. ranks higher than 87% of the stocks. Editas Medicine Inc fell 3.61% over the past month, closing at $ 64.72 on August 24. During that time, the stock fell to $ 58.20 and $ 73.03. EDIT has an average Buyer’s recommendation. The company has an average price target of $ 57.44.

Editas Medicine Inc has a long-term technical rank of 68. This means that trading in the last 200 trading days has placed the company in the top half of stocks with 32% of the market with a top score. In the biotech industry which is number 131 on this metric, EDIT ranks better than 84% of stocks.

Important dates for investors in EDIT:

-Editas Medicine Inc is expected to release its results on 2/11/2021. When its results were last released, the company posted EPS of – $ 2.60. – We do not have a fixed dividend date for Editas Medicine Inc at this time. Click here for the full report on Editas Medicine Inc (EDIT)